Ovid Therapeutics ownership filing reports that Eventide Asset Management, LLC and related filers disclose a 12,773,577-share position in Ovid's common stock, representing 7.3% of outstanding shares as of March 31, 2026. The filing states Eventide holds these shares as investment adviser to the Eventide Healthcare & Life Sciences Fund.
The statement is filed on behalf of Eventide, Finny Kuruvilla, M.D., Ph.D., and Robin C. John and includes the Rule 13d-4 disclaimer that the individual filers disclaim beneficial ownership. The filing is a passive ownership disclosure under Schedule 13G.
Positive
None.
Negative
None.
Insights
Institutional fund reports a 7.3% stake in Ovid Therapeutics (12.8M shares).
Eventide Asset Management, as investment adviser to the Eventide Healthcare & Life Sciences Fund, is shown as the beneficial owner of 12,773,577 shares, equal to 7.3% of outstanding common stock as of March 31, 2026. The filing is a Schedule 13G passive ownership disclosure.
Ownership is disclosed jointly with two named individuals who disclaim beneficial ownership per Rule 13d-4. Subsequent filings would show changes if Eventide adjusts its position.
Filing follows Rule 13d-4 passive reporting and includes standard disclaimers.
The statement identifies the issuer, CUSIP 690469101, and provides issuer address and filer addresses. It specifies voting and dispositive power allocations: Eventide holds sole voting/dispositive power, while Kuruvilla and John report shared voting/dispositive power.
This filing documents a >5% position triggering Schedule 13G reporting; any material change in ownership or intent would require amendment or different form.
Key Figures
Shares owned:12,773,577 sharesPercent of class:7.3%CUSIP:690469101
3 metrics
Shares owned12,773,577 sharesBeneficial ownership by Eventide Healthcare & Life Sciences Fund as of March 31, 2026
Percent of class7.3%Percent of outstanding common stock as of March 31, 2026
CUSIP690469101Issuer's CUSIP for the common stock reported in the Schedule 13G
"Item 1. | (a) | Name of issuer: Ovid Therapeutics Inc."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Rule 13d-4 disclaimerregulatory
"In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership"
beneficial ownerfinancial
"As of March 31, 2026, Eventide Asset Management, LLC ... is the beneficial owner of 12,773,577 shares"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
investment adviserregulatory
"by virtue of being the investment adviser to Eventide Healthcare & Life Sciences Fund"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Ovid Therapeutics Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
690469101
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Eventide Asset Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
12,773,577.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
12,773,577.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,773,577.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.3 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Finny Kuruvilla, M.D., Ph. D.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
12,773,577.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
12,773,577.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,773,577.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.3 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Robin C. John
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
12,773,577.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
12,773,577.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,773,577.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.3 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Ovid Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
441 Ninth Avenue, 14th floor, New York, NY 10001
Item 2.
(a)
Name of person filing:
(i) Eventide Asset Management, LLC ("Eventide")
(ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla")
(iii) Robin C. John ("John")
(b)
Address or principal business office or, if none, residence:
Eventide, Kuruvilla and John:
One International Place, Suite 4210
Boston, Massachusetts 02110
(c)
Citizenship:
Eventide: Delaware
Kuruvilla: United States
John: United States
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
690469101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
(i) Eventide: 12,773,577
(ii) Kuruvilla: 12,773,577
(iii) John: 12,773,577
(b)
Percent of class:
(i) Eventide: 7.3%
(ii) Kuruvilla: 7.3%
(iii) John: 7.3%
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
As of March 31, 2026, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 12,773,577 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Healthcare & Life Sciences Fund which is a registered investment company.
As of March 31, 2026, the Eventide Healthcare & Life Sciences Fund held 12,773,577 shares of the Issuer's Common Stock, representing 7.3% of the Issuer's outstanding Common Stock.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Eventide reports beneficial ownership of 12,773,577 shares, equal to 7.3% of Ovid's outstanding common stock as of March 31, 2026. The shares are held through the Eventide Healthcare & Life Sciences Fund, for which Eventide is adviser.
Who filed the Schedule 13G for OVID?
The filing was made by Eventide Asset Management, LLC and two associated persons, Finny Kuruvilla, M.D., Ph.D. and Robin C. John, listing Eventide as the investment adviser and providing its Boston address.
Does the filing claim individual beneficial ownership?
No; the filing includes a Rule 13d-4 disclaimer. It states that the named individuals expressly disclaim beneficial ownership of the securities covered by the statement.
What voting or dispositive powers are disclosed?
The filing shows Eventide with sole voting and sole dispositive power for 12,773,577 shares, while Kuruvilla and John are reported with shared voting and shared dispositive power over the same 12,773,577 shares.
What date is the ownership figure measured?
The ownership amount and percentage are stated as of March 31, 2026. The Schedule 13G discloses the fund's holdings on that specific date, triggering the >5% reporting requirement.
